Attenuation of MPTP-induced dopaminergic neurotoxicity by a serotonin uptake blocker

W. J. Brooks, M. F. Jarvis, G. C. Wagner

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Monoamine oxidase-B (MAO-B) has been determined to be the enzyme responsible for the conversion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into its toxic metabolite 1-methyl-4-phenylpyridine ion (MPP+). Since this enzyme has been localized primarily in astrocytes and serotonergic neurons, it would appear that MPP+ is being produced outside the dopaminergic neurons. To investigate this possibility, the administration of MPTP was preceded by systemically administered fluoxetine. In keeping with its demonstrated ability to inhibit uptake into serotonergic neurons and serotonin uptake into astrocytes, fluoxetine pretreatment resulted in a significant attenuation of MPTP-induced depletions of striatal dopamine and serotonin concentration. These results support the extra-dopaminergic production of MPP+.

Original languageEnglish (US)
Pages (from-to)85-90
Number of pages6
JournalJournal of Neural Transmission
Volume71
Issue number2
DOIs
StatePublished - Jun 1988

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Keywords

  • Fluoxetine
  • MPTP
  • astrocytes
  • dopamine
  • parkinsonism
  • serotonin

Fingerprint Dive into the research topics of 'Attenuation of MPTP-induced dopaminergic neurotoxicity by a serotonin uptake blocker'. Together they form a unique fingerprint.

Cite this